Organ regeneration specialist Biostage (NSDQ:BSTG) said it asked the FDA for orphan drug status for its Cellspan artificial esophagus. If the request is granted, Holliston, Mass.-based Biostage, formerly know as Harvard Apparatus Regenerative Technology, would win 7 years of market exclusivity after FDA approval, plus tax credits and an exemption from the federal safety watchdog’s drug registration […]
Biostage Inc
Harvard Apparatus rebrands as Biostage
Harvard Apparatus Regenerative Technology (NSDQ:HART) said today it is rebranding as Biostage, Inc. and shifting its Nasdaq symbol to “BSTG”, effective April 1. The company said the brand shift “reflects the company’s broad commitment and expertise in pioneering the development of bioengineered organ implants for the esophagus, bronchus and trachea.” “The Biostage name change reflects the evolution of […]
